TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02070835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autologous skin cell
Description: autologous skin cell and skin graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin graft
Description: split-thickness skin graft
Study: NCT01200654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
Study: NCT04530006

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride
Description: Patients who are eligible for the study will be administered a regular 200 mg dose of FDA approved drug amantadine. This will be done at the following timepoints:~1. Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~2. Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~3. Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)
Study: NCT00496756

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
Study: NCT03398031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
Study: NCT01347541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
Study: NCT06583057

Intervention type: PROCEDURE
Intervention: Thermal ablation
Description: Patients who underwent thermal ablation were performed in the outpatient clinic's operating room under local anesthesia. Thermal ablation was performed under real-time ultrasound-guided. The 18-G bipolar radiofrequency applicator with a 0.9 cm active tip (CelonProSurge micro 100-T09, Olympus Surgical Technologies Europe) , or a 16-G/17-G cooled microwave antenna with a 0.3 cm tip (ECO-100A1, YIGAO MWA system Co., Ltd; KY-2000, Kangyou Medical, Nanjing, China) was used during ablation.

Intervention type: PROCEDURE
Intervention: Thyroid lobectomy
Description: Patients who underwent thyroid lobectomy were performed in the operating theater under general anesthesia. Lobectomy (or lobectomy plus isthmusectomy) with prophylactic central neck dissection were performed.
Study: NCT01347541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing is designed to address alcohol and drug use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-Approved Anti-Anxiety Medications
Description: Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control
Description: Standard care control includes the usual treatment for injured trauma survivors
Study: NCT00921180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and peginterferon alfa-2a
Description: Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and peginterferon
Description: Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
Study: NCT02162342

Intervention type: OTHER
Intervention: Rehabilitative treatment
Description: Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
Study: NCT06583057

Intervention type: PROCEDURE
Intervention: Thyroid lobectomy
Description: Patients who underwent thyroid lobectomy were performed in the operating theater under general anesthesia. Lobectomy (or lobectomy plus isthmusectomy) with prophylactic central neck dissection were performed.
Study: NCT02522208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BiDil XR
Description: fixed combination capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BiDil XR
Description: fixed combination capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BiDil Immediate Release (IR)
Description: fixed combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BiDil Immediate Release (IR)
Description: fixed combination tablet
Study: NCT02320500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy
Description: standard of care physiotherapy once every 2 weeks for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial-specific therapy
Description: Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
Study: NCT02437955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate fortified bread with tea
Description: Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ferrous sulfate fortified bread with water
Description: Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
Study: NCT05334641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening Music
Description: The patients in the experimental group were listened to music.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Not Listening Music
Description: The control group was not listened to music.
Study: NCT02372279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo observation
Description: In EO group, conventional observations will be made.
Study: NCT04048291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk walking and balance training
Description: 6 months of combined brisk walking and balance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb exercise
Description: 6 month of hand dexterity training
Study: NCT02929888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysine Acetilsalicilate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT00934167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heparin sodium - Hipolabor
Description: 5.000 UI/0,25mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium - APP
Description: 5.000 USP/mL
Study: NCT01422980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1- Test dairy product containing specific ingredients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- Control dairy product without specific ingredients
Study: NCT04250142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-etching Adhesive
Description: A Self-etching adhesive will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: A conventional glass ionomer will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
Study: NCT01208805

Intervention type: BEHAVIORAL
Intervention: Recording spinal cord evoked potentials
Description: Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
Study: NCT01574690

Intervention type: DEVICE
Intervention: Mespere Venus System
Description: For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam

Intervention type: PROCEDURE
Intervention: Right heart catheterization (RHC)
Description: Invasive procedure to assess CVP. Standard of care.

Intervention type: PROCEDURE
Intervention: Physical examination of jugular vein
Description: Physicians assess CVP using the subject's jugular vein.
Study: NCT03389347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow aspirate and blood

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Throughput Screening
Description: Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03260725

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-Child Interaction Therapy (PCIT)
Description: PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered PCIT (I-PCIT)
Description: I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
Study: NCT02443597

Intervention type: OTHER
Intervention: ultrasound
Description: trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening

Intervention type: OTHER
Intervention: ultrasound
Description: trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
Study: NCT02437955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate fortified bread with tea
Description: Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate fortified bread with water
Description: Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
Study: NCT01165138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/Vilanterol Inhalation Powder
Description: Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate Inhalation Powder
Description: Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhaltion Powder
Description: Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
Study: NCT01567072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only placebo treatment instead of NSAID painkillers
Study: NCT01982942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibudilast
Description: Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
Study: NCT03596307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha extract
Description: Shoden 180 mg capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ashwagandha extract
Description: Shoden 180 mg capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 180 mg (Sucrose) capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 180 mg (Sucrose) capsule.
Study: NCT04384276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Weigh Easy System
Description: By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.

Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective Control
Description: No interventions will be administered to the historical control group.
Study: NCT03212872

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endoscopy
Study: NCT04209140

Intervention type: DRUG
Intervention: lithium treatment
Description: Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe.
Study: NCT00290329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax ACWY
Description: 1 subcutaneous injection.
Study: NCT01226758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (FLU-v)
Description: FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (adjuvant only)
Description: Single subcutaneous injection of adjuvant
Study: NCT03266211

Intervention type: OTHER
Intervention: Questionnaire Patients
Description: Patient will have to answer a quiz which is about their vaccination against tetanus.

Intervention type: OTHER
Intervention: Questionnaire General practitioner
Description: General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
Study: NCT02956408

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
Study: NCT03609775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: One tablet of 50 mg ACT-541468 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: One tablet of 50 mg ACT-541468 will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT-541468 placebo
Description: Matching ACT-541468 placebo will be administered orally as 1 tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT-541468 placebo
Description: Matching ACT-541468 placebo will be administered orally as 1 tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol 10%
Description: Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol 10%
Description: Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol placebo
Description: Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol placebo
Description: Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
Study: NCT02051634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Papaya Preparation (FPP)
Description: A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Papaya Preparation (FPP)
Description: A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
Study: NCT03665688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient Dilapan-S
Description: After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L\&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L\&D unit for standard protocol of labor induction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Dilapan-S
Description: After Dilapan-S placement, subjects will be admitted to L\&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated.
Study: NCT03549715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg IV D1 every 28 days (2 doses for each patient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg IV D1 every 28 days (2 doses for each patient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg IV D1 every 28 days ((2 doses for each patient)
Study: NCT01080898

Intervention type: OTHER
Intervention: tests
Description: color photographs, FLUORESCEIN angiography and OCT
Study: NCT03365700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
Study: NCT03549715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVAC Protocol
Description: 1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVAC Protocol
Description: 1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1